[Perspectives] Yale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomes

A 71-year-old male patient was diagnosed with localised prostate cancer with a Gleason score of 10 and was initially treated with radiotherapy and leuprolide. 2 years later, he developed oligometastatic recurrence in the scapula, which was irradiated, and he continued on leuprolide therapy. After another 3 years, he developed recurrence with widespread adenopathy, for which he received multiple lines of therapy including docetaxel, sipleucel-T, enzalutamide, and abiraterone over 5 years. He was then referred to the Yale Cancer Center and enrolled in two successive clinical trials, with disease progression.

Source: The Lancet Oncology - December 30, 2017 Category: Cancer & Oncology Authors: Michael Cecchini, Zenta Walther, Jeffrey L Sklar, Ranjit S Bindra, Daniel P Petrylak, Joseph P Eder, Sarah B Goldberg Tags: Perspectives Source Type: research